Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
Youyou Zhang(University of Pennsylvania), Lin Zhang(Simon Fraser University), Zhongyi Hu(AstraZeneca (South Korea)), János L. Tanyi(Penn Center for AIDS Research), Jie Huang(Institute for Reproductive Health), Omid Tavana(Bioscience Research), Meixiao Long(The Ohio State University), Kathleen T. Montone(University of Pennsylvania), Jianfeng Shen(Shanghai Jiao Tong University), Bingwei Wang(Nanjing University of Chinese Medicine), Yi Fan(Academy of Military Medical Sciences), Jiao Yuan(AstraZeneca (South Korea)), Mu Xu(AstraZeneca (South Korea)), Junjie Jiang(Wuhan Children's Hospital), Ho Man Chan, Xiaowen Hu(Lanzhou University)
Cited by 1